Antibody Technologies

A few core antibody technologies, reviewed in Ref. 50, have been crucially important to the development of all marketed antibody therapeutics (Fig. 2) as well as to virtually aU antibody therapeutics in clinical development. These core antibody technologies are reviewed in this section hybridoma, chimerization, humanization, and human antibodies through phage libraries or transgenic mice. Approximately 11 years elapsed between the advent of hybridoma, chimerization. 

Marcel Dekker, Inc. 270Madison Avraue. New Yoric. NewYoik 10016 

Marcel Dekker, Inc. 270 Madison Avenue. New York, New York 10016 

Panorex was more efficacious in the treatment of minimal residual disease and micrometastases (53,54) than in bulky metastatic disease (55). This finding is widely anticipated as a paradigm that will be broadly applicable to other antitumor antibodies. 

---

Biotech products based on recombinant DNA, gene expression or hybridoma/monoclonal antibody technologies. 

Adtveoitages. The antibody technology is remarkably convenient. It requires only that a significant fraction of FLPEP be receptor bound ( 10%). The assay can be set up in a few minutes and is applicable to membranes, permeabilized cells, cells, or any other preparation in which the receptor concentration is in the range of 1 niV or greater. We use this assay routinely to analyze ligand dissociation kinetics. 

The advent of genetic engineering and monoclonal antibody technology underpinned the establishment of literally hundreds of start-up biopharmaceutical (biotechnology) companies in... 

During the 1980s, rapid developments in the areas of recombinant DNA technology and monoclonal antibody technology contributed to a greater depth of understanding of cytokine biology ... 

Monoclonal antibody technology entails isolation of such B-lymphocytes, with subsequent fusion of these cells with transformed (myeloma) cells. Many of the resultant hybrid cells retain immortal characteristics, while producing large quantities of the monospecific antibody. These hybridoma cells can be cultured long term to effectively produce an inexhaustible supply of the monoclonal antibody of choice. 

Humira (EU USA also sold as Trudexa in EU) (adalimumab r (anti-TNF) human monoclonal antibody created using phage display technology Cambridge Antibody Technologies Abbott (USA) Abbott (EU) Rheumatoid arthritis... 

A breakthrough for tissue printing, at least for the botanical sciences, came when Cassab and Varner (3) combined the use of nitrocellulose and antibody technology. They placed sections of a freshly cut soybean seed on nitrocellulose membranes and probed the resulting imprints using specific antibodies. They were able to show that soluble extensin protein is primarily localized in the seed coat and vascular tissues. 

I would like to acknowledge Dr. Jack Dunne, who introduced me to monoclonal antibody technology and immunocytochemistry on whole-mounts and... 

The combination of the specificity of the antigen-antibody interaction with the exquisite sensitivity of fluorescence detection and quantitation yields one of the most widely applicable analytical tools in cell biology (1). Within the last decade, flow cytometry (FCM) has become an integral part of basic immunological research. Elaboration of this technology has been intensively stimulated by a rapidly growing sophistication in monoclonal antibody technology and vice versa (2). 

A further advance in antibody technology is the development of transgenic mouse human strains. XenoMouse animals have been engineered in such a way that they now produce exclusively human antibodies rather than murine antibodies when immunized. The use of XenoMouse animals to produce MAbs avoids the need for any engineering of the antibody genes, since the products are already 100% human protein. XenoMouse animals are fully compatible with standard hybridoma technology and can be readily adopted by laboratories experienced in monoclonal antibody production [56]. 

Progress in the field of drug targeting has been slow till thirty years ago. With the advent of the monoclonal antibody technology in the mid seventies of the last century as well as the development of liposomal devices as carriers did the drug targeting field expand and did the clinical application become a feasible aim. 

Recent advances in antibody technology provide simple dip-stick methods that can monitor mitochondrial protein expression compared to a nuclear-encoded protein. 

Liddell, J. (1995). Antibody Technology. BIOS Scientific, Oxford. 

Antibody Resource, http //www.antibodyresource.com/educational.html Campbell, A.M. (1984). Monoclonal Antibody Technology. Elsevier, Amsterdam. 

Harper, K., Ziegler, A. (1997). Applied antibody technology. Trends Biotechnol., 15, 41-42. 

Polymer-protein conjugates (see Fig. 11.1 a). The phenomenal advances in molecular cloning and monoclonal antibody technology have rendered... 

---